share_log

China Meheco Group (SHSE:600056) Takes On Some Risk With Its Use Of Debt

China Meheco Group (SHSE:600056) Takes On Some Risk With Its Use Of Debt

中國醫藥集團(上證: 600056)在使用債務方面存在一定風險
Simply Wall St ·  08/03 20:06

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that China Meheco Group Co., Ltd. (SHSE:600056) does use debt in its business. But the more important question is: how much risk is that debt creating?

戴維·伊本(David Iben)的這句話說得好:“波動性不是我們關心的風險。我們關心的是避免資本的永久損失。” 當我們考慮一家公司的風險有多大時,我們總是喜歡看它使用債務的情況,因爲債務過載可能會導致毀滅。我們可以看到,中國醫藥集團股份有限公司(SHSE:600056)的確在其業務中使用了債務。但更重要的問題是:這些債務創造了多少風險?

When Is Debt A Problem?

什麼時候負債才是一個問題?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we think about a company's use of debt, we first look at cash and debt together.

債務是幫助企業增長的工具,但如果企業無法償還債權人,那麼它就存在於債權人的擺佈之下。最終,如果公司無法實現償還債務的法律義務,股東可能會一無所有。然而,更常見(但仍然昂貴)的情況是公司必須以廉價的股票價格稀釋股東,只是爲了控制債務。當然,許多公司使用債務來資助增長,沒有任何負面影響。當我們考慮企業使用債務的情況時,我們首先會考慮現金和債務的總量。

What Is China Meheco Group's Debt?

中國醫藥集團的債務是什麼?

The chart below, which you can click on for greater detail, shows that China Meheco Group had CN¥5.50b in debt in March 2024; about the same as the year before. However, it does have CN¥2.63b in cash offsetting this, leading to net debt of about CN¥2.87b.

下面的圖表(單擊可獲得更多詳細信息)顯示,中國醫藥集團於2024年3月的債務爲55億元人民幣,與去年大致相同。然而,它確實有26.3億元人民幣的現金抵消這筆債務,導致淨債務約爲28.7億元人民幣。

big
SHSE:600056 Debt to Equity History August 4th 2024
SHSE:600056權益爲債務歷史記錄的圖表,截至2024年8月4日。

A Look At China Meheco Group's Liabilities

看一下中國醫藥集團的負債情況

According to the last reported balance sheet, China Meheco Group had liabilities of CN¥18.5b due within 12 months, and liabilities of CN¥4.81b due beyond 12 months. Offsetting this, it had CN¥2.63b in cash and CN¥17.9b in receivables that were due within 12 months. So its liabilities outweigh the sum of its cash and (near-term) receivables by CN¥2.79b.

根據最近公佈的資產負債表,中國醫藥集團截至12個月內到期的負債爲185億元人民幣,超過12個月到期的負債爲48.1億元人民幣。抵消這一點的是,它擁有26.3億元人民幣的現金和179億元人民幣的應收賬款,這些賬款在12個月內到期。因此,其負債超過其現金和(短期)應收賬款總和279億元人民幣。由於中國醫藥集團公開交易的股票總價值爲156億元人民幣,因此這種負債水平似乎不太可能構成重大威脅。儘管如此,顯然,我們應該繼續監控其資產負債表,以免情況變得更糟。

Since publicly traded China Meheco Group shares are worth a total of CN¥15.6b, it seems unlikely that this level of liabilities would be a major threat. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse.

中國醫藥集團的債務與息稅折舊及攤銷前利潤之比(債務/EBITDA)爲1.9,巧妙而負責地使用債務。而且它擁有相當有吸引力的利息保障(EBIt爲7.2倍的利息支出),這確實沒有消除這種印象。不幸的是,中國醫藥集團的EBIt在過去四個季度中下降了19%。如果收益率繼續以這個速度下降,那麼處理債務將比帶着三個5歲以下的孩子去一家花哨的餐廳容易得多。在分析債務水平時,資產負債表是顯然的起點。但是,您不能孤立地看待債務;因爲中國醫藥集團將需要盈利來償還債務。因此,在考慮債務時,絕對有必要看一下收益趨勢。點擊此處以獲取交互式快照。

We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). Thus we consider debt relative to earnings both with and without depreciation and amortization expenses.

通過查看公司的淨債務與利息、稅、折舊、攤銷前利潤(EBITDA)之比以及它的利息費用(利息覆蓋率)可以衡量一個公司的債務負擔與收益能力。因此,我們考慮將債務與有無計算折舊和攤銷費用的收益相對比。

With a debt to EBITDA ratio of 1.9, China Meheco Group uses debt artfully but responsibly. And the alluring interest cover (EBIT of 7.2 times interest expense) certainly does not do anything to dispel this impression. Unfortunately, China Meheco Group's EBIT flopped 19% over the last four quarters. If earnings continue to decline at that rate then handling the debt will be more difficult than taking three children under 5 to a fancy pants restaurant. When analysing debt levels, the balance sheet is the obvious place to start. But you can't view debt in total isolation; since China Meheco Group will need earnings to service that debt. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

最後,企業需要自由現金流來償還債務;會計利潤根本不能勝任。因此,我們明確需要查看EBIt是否導致相應的自由現金流。在過去三年中,中國醫藥集團的自由現金流相當於其EBIt的28%,低於我們的預期。這種較弱的現金轉換使處理負債更加困難。

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. So we clearly need to look at whether that EBIT is leading to corresponding free cash flow. In the last three years, China Meheco Group's free cash flow amounted to 28% of its EBIT, less than we'd expect. That weak cash conversion makes it more difficult to handle indebtedness.

中國醫藥集團的EBIt增長率在這種分析中確實是一個真正的負面因素,儘管我們考慮的其他因素都使它看起來更好。但是好的一面是,它用EBIt覆蓋利息支出的能力也不錯。我們還應該注意,與中國醫藥集團類似的醫療保健行業公司通常會毫無問題地使用債務。當我們考慮所有討論的因素時,我們認爲中國醫藥集團在使用債務方面存在一些風險。因此,雖然這種槓桿率確實增加了股權回報率,但我們並不希望看到它從這裏開始增加。毫無疑問,我們從資產負債表上了解債務的大部分。但是,並非所有投資風險都駐留在資產負債表上——遠非如此。我們已確定與中國醫藥集團有3個警告信號(至少有1個讓我們不太滿意),了解它們應該是您投資過程的一部分。

Our View

我們的觀點

China Meheco Group's EBIT growth rate was a real negative on this analysis, although the other factors we considered cast it in a significantly better light. But on the bright side, its ability to to cover its interest expense with its EBIT isn't too shabby at all. We should also note that Healthcare industry companies like China Meheco Group commonly do use debt without problems. When we consider all the factors discussed, it seems to us that China Meheco Group is taking some risks with its use of debt. So while that leverage does boost returns on equity, we wouldn't really want to see it increase from here. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. We've identified 3 warning signs with China Meheco Group (at least 1 which doesn't sit too well with us) , and understanding them should be part of your investment process.

當然有一些行業使用債務不會有問題,醫療保健行業正是其中之一。對於其他行業,下降率也有所鼓舞。當我們考慮所有因素時,我們認爲中國醫藥集團在使用債務方面存在一些風險。雖然這種槓桿化確實提高了股權回報率(ROE),但我們不希望它進一步增加。我們需要看到公司產生一些實際的自由現金流以用於償還債務,而不僅僅是會計利潤。 這篇文章列出的數據和意見都是根據公司近期的情況得出的。 我們對數據的準確性沒有任何保證。行業應被翻譯爲行業板塊,學習應被翻譯爲課堂,業務應被翻譯爲業務,看跌應被翻譯爲put,基金應被翻譯爲基金,分享應被翻譯爲分享,can應被翻譯爲可以,中國醫藥集團應被翻譯爲中國醫藥,開始控件應被翻譯爲開始,自由現金流應被翻譯爲自由現金流,其他應被翻譯爲其他,所有板塊應被翻譯爲所有板塊。

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

如果您有興趣投資能夠在不負債的情況下增長利潤的企業,請查看這份免費列表,其中列出了在資產負債表上擁有淨現金的成長型企業。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論